Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | XDH | P47989 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23874985 | 0.90 | XDH (0.52) | MAOBXDHKMT2A | |
| SCHEMBL21884785 | 0.89 | MAOB (0.47) | MAOBXDH | |
| SCHEMBL21807879 | 0.83 | XDH (0.49) | MAOBXDHSLC6A2SLC6A3KMT2A | |
| SCHEMBL21884784 | 0.81 | XDH (0.41) | MAOBXDH | |
| SCHEMBL23875066 | 0.80 | XDH (0.41) | MAOBXDH | |
| SCHEMBL5024877 | 0.78 | XDH (0.60) | MAOBXDHSLC6A2SLC6A3KMT2A | |
| SCHEMBL1534113 | 0.77 | XDH (0.48) | MAOBXDHKMT2ATDP1 | |
| SCHEMBL23874987 | 0.76 | PTPN1 (0.40) | MAOBXDH | |
| SCHEMBL3926837 | 0.74 | TDP1 (0.58) | SLC6A2SLC6A3KMT2ATDP1 | |
| SCHEMBL23874972 | 0.74 | XDH (0.55) | MAOBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | MAOB 2027/4885XDH 1075/4885SLC6A2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.